Journal article
Mineralocorticoid Antagonism in Heart Failure Established and Emerging Therapeutic Role
Abstract
The pathophysiology of heart failure (HF) is related to the overactivation of the mineralocorticoid receptor, leading to fluid retention and adverse myocardial remodeling. Although mineralocorticoid receptor antagonists (MRAs) are recommended for the treatment of heart failure with reduced ejection fraction (HFrEF), they remain underused due to adverse effects such as hyperkalemia; and their efficacy is controversial in heart failure with …
Authors
Chang J; Ambrosy AP; Vardeny O; Van Spall HGC; Mentz RJ; Sauer AJ
Journal
JACC Heart Failure, Vol. 12, No. 12, pp. 1979–1993
Publisher
Elsevier
Publication Date
December 2024
DOI
10.1016/j.jchf.2024.08.007
ISSN
2213-1779